Renovos

Renovos is a new spinout capitalising on the decades of world-class orthopaedic research from the University of Southampton. We will apply this knowledge to provide regenerative medicine solutions to orthopaedic challenges, offering the orthopaedic research community new tools to develop the next generation of medicines, whilst supporting the development of our own proprietary therapeutic that has the potential to revolutionise bone healing.

Renovos will be generating revenues immediately through direct-to-customer sales of its research-grade products and high-value services. There are hundreds of orthopaedic R&D centres across the EU/USA, with a conservative per centre spend of £15k p.a. on stem cells alone, resulting in a market of ~£5m (growing at 20% CAGR). Our therapeutic platform targets the orthobiologics market ($5bn), with initial application to tibial bone fractures, which fail to heal in up to half of all clinical cases (500k tibial fractures p.a. in US at ~$20-50k total cost per treatment). Our technology development pipeline will address enhancing orthopaedic devices and the veterinary field.

Renovos is leveraging the expertise of the University of Southampton research teams and its collaborative network as our customer base. We are founded by the leads of the University of Southampton orthopaedic research team and local entrepreneurs brining decades of commercial experience, supported by a network of orthopaedic surgeons to drive the clinical development of our therapeutic.

We are seeking £250k seed investment to set up the company and labs, leveraging the secured £300k non-dilutive Innovate UK grant funding to reach key milestones in the therapeutic development.

What is your innovation?

Renovos’ nanoclay-gels have the potential to revolutionise bone healing through a controlled and localised release of therapeutics, offering a step-change in their safety and effectiveness.

Venturefest Oxford

The 2019 event will be on Wednesday 11th September at Oxford Brookes University.